Loading clinical trials...
Loading clinical trials...
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis. New evidence indicates that NAFL...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Aarhus
NCT07093346 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), and more
NCT06115876 · Diabetes Mellitus Type 2, Diabetes Mellitus Type 1, NAFLD - Nonalcoholic Fatty Liver Disease, and more
NCT02581085 · End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, and more
NCT03467217 · NAFLD - Nonalcoholic Fatty Liver Disease
Department of Diabetes and Hormone diseases in Aarhus University Hopital
Skejby, Aarhus N
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions